Deva Holding A.S.

Deva Holding A.S. is a topic of great relevance today, since it has aroused the interest of numerous people around the world. Since its emergence, it has generated a wide range of opinions and discussions, as well as having an impact on various areas of society. Its importance lies in the influence it has on people's daily lives, as well as its potential to generate significant changes in different aspects. In this article, we will explore in detail the various facets and repercussions of Deva Holding A.S., with the aim of providing a complete and enriching analysis of this topic that is so relevant today.

Deva Holding A.S.
Company typePharmaceutical Company
BİST: DEVA
IndustryHealthcare
FoundedSeptember 22, 1958
HeadquartersIstanbul, Turkey
Key people
Mr. Philipp Haas (Chairman and CEO)
ProductsPharmaceuticals
RevenueUS$480M (2023)
Number of employees
2,300
Websitewww.deva.com.tr

Pharmaceutical manufacturer Deva Holding A.S. is a Turkish Fortune 500 company with annual revenue of more than US$480 million and a staff of approximately 2,300 across its operations in Turkey, Germany, USA and New Zealand.[1][2][3]

Background

Established in 1958, Deva Holding A.S. is Turkey’s second-largest pharmaceutical company and is primarily engaged in the production and distribution of pharmaceutical and veterinary products.[4][5]

References

  1. ^ "Antibiotic Long Distance Run". Fortune Magazine. 19 July 2019. Archived from the original on 2019-09-05. Retrieved 15 September 2019.
  2. ^ "5 Minutes Interview with: Philipp Haas - Deva". Pharma Horizon Magazine. 4 May 2017. Archived from the original on 2019-10-28. Retrieved 15 September 2019.
  3. ^ "Philipp Haas – Chairman & CEO, DEVA, Turkey". Pharma Boardroom Magazine. 29 November 2018. Archived from the original on 2019-10-28. Retrieved 15 September 2019.
  4. ^ "» 5 minutes interview with: Philipp Haas – DEVA". TKS Publisher. Retrieved 2019-10-28.
  5. ^ "DEVA.IS - Deva Holding AS Profile | Reuters". www.reuters.com. Retrieved 2019-10-28.